Name|Full Name|Type|Unit|Description
sample_id|Sample ID|chr|-|Unique string identifying each subject
patient_cohort|Patient's Cohort|chr|-|Cohort 1 = previously used samples; Cohort 2 = newly added samples
sample_origin|Sample Origin|chr|-|BPTB: Barts Pancreas Tissue Bank, London, UK; ESP: Spanish National Cancer Research Centre, Madrid, Spain; LIV: Liverpool University, UK; UCL: University College London, UK
age|Age of subject|dbl|-|Age in years
sex|Sex of subject|chr|-|M = male; F = female
diagnosis|Diagnosis|dbl|-|1 = control (no cancer); 2 = benign hepatobiliary disease; 3 = PDA (pancreatic cancer)
stage|Stage|chr|-|The stage of the disease (IA, IB, IIA, IIB, III, IV)
benign_sample_diagnosis|Benign Sample's Diagnosis|chr|-|The diagnosis for those with a benign diagnosis
plasma_CA19_9|Plasma CA19-9|dbl|U/ml|Blood plasma levels of CA19-9 monoclonal antibody, usually elevated when pancreatic cancer
creatinine|Creatinine|dbl|mg/ml|Urinary biomarker of kidney function
LYVE1|LYVE1|dbl|ng/ml|Urinary levels of Lymphatic Vessel Endothelial Hyaluronan receptor 1
REG1B|REG1B|dbl|ng/ml|Urinary levels of Regenerating Family Member 1 Beta
TFF1|TFF1|dbl|ng/ml|Urinary levels of Trefoil Factor 1
REG1A|REG1A|dbl|ng/ml|Urinary levels of Regenerating Family Member 1 Alpha